12:00 AM
Jun 09, 2014
 |  BC Week In Review  |  Company News  |  Deals

Celgene, NanoString deal

NanoString will develop an in vitro companion diagnostic using its nCounter Analysis System to screen patients for a pivotal trial of Revlimid lenalidomide in diffuse large B cell lymphoma (DLBCL). The trial is slated to start in late 2014 or early 2015. NanoString will receive a $5.8 million upfront payment...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >